title: Forty-year journey of angiogenesis translational research.
abstract: Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy.
authors.affiliation: Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden. yihai.cao@ki.se
authors.forename: Yihai
authors.initials: Y
authors.lastname: Cao
authors.forename: Jack
authors.initials: J
authors.lastname: Arbiser
authors.forename: Robert J
authors.initials: RJ
authors.lastname: D'Amato
authors.forename: Patricia A
authors.initials: PA
authors.lastname: D'Amore
authors.forename: Donald E
authors.initials: DE
authors.lastname: Ingber
authors.forename: Robert
authors.initials: R
authors.lastname: Kerbel
authors.forename: Michael
authors.initials: M
authors.lastname: Klagsbrun
authors.forename: Sharon
authors.initials: S
authors.lastname: Lim
authors.forename: Marsha A
authors.initials: MA
authors.lastname: Moses
authors.forename: Bruce
authors.initials: B
authors.lastname: Zetter
authors.forename: Harold
authors.initials: H
authors.lastname: Dvorak
authors.forename: Robert
authors.initials: R
authors.lastname: Langer
mesh_terms: D015415:Biomarkers; D016222:Fibroblast Growth Factor 2 / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000098:blood supply; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
chemical_list: D015415:Biomarkers; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2